Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers Juniper Point2023-12-01T00:56:24+00:0011.29.2023| Read More
Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community Juniper Point2023-12-01T00:56:25+00:0011.21.2023| Read More
Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Juniper Point2023-12-01T00:56:25+00:0011.03.2023| Read More
